Antibody response after varicella vaccination in children treated with budesonide inhalation suspension or non-steroidal conventional asthma therapy

International Journal of Clinical Practice

Volumn 60, Issue 12, 2006, Pages 1548-1557

  Murphy, K ^a   Ververeli, K ^b   Harvey, B M ^c   Duke, A L ^d   Chapas crilly, J ^e   Uryniak, T ^e   Lyzell, E ^e   Mezzanotte, W ^e  

^a Midwest Children's Chest Physicians   (United States)

^b Allergy and Asthma Consultants NJ/PA   (United States)

^c Harvey Pediatric Research   (United States)

^d Arkansas Pediatric Clinic   (United States)

^e ASTRAZENECA   (United Kingdom)

Author keywords

Budesonide inhalation suspension; Immunogenicity; Live varicella vaccine; Paediatric asthma patients

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CHICKENPOX VACCINE; CROMOGLYCATE DISODIUM; FORMOTEROL FUMARATE; GLYCOPROTEIN; IPRATROPIUM BROMIDE; IPRATROPIUM BROMIDE PLUS SALBUTAMOL SULFATE; LEVALBUTEROL; LIVE VACCINE; MONTELUKAST; SALBUTAMOL; SALMETEROL XINAFOATE; VIRUS ANTIBODY; ZAFIRLUKAST;

ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; ASTHMA; CHILD; CLINICAL TRIAL; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG TOLERABILITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FEVER; HUMAN; IMMUNOGENICITY; INJECTION SITE REACTION; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; OTITIS MEDIA; PARALLEL DESIGN; PATIENT SELECTION; PRIORITY JOURNAL; RESTLESSNESS; RISK FACTOR; SUSPENSION; UPPER RESPIRATORY TRACT INFECTION; VACCINATION REACTION; VARICELLA ZOSTER VIRUS; VOMITING;

ADMINISTRATION, INHALATION; ANTI-ASTHMATIC AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODY FORMATION; ASTHMA; BUDESONIDE; CHICKENPOX; CHICKENPOX VACCINE; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; HUMANS; INFANT; PATIENT COMPLIANCE;

EID: 33750978984     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2006.01189.x     Document Type: Article

References (44)

1. American Lung Association. Trends in Asthma Morbidity and Mortality. New York, NY: Epidemiology and Statistics Unit, Research and Program Services, 2005.
2. National Asthma Education and Prevention Program. Expert panel report: guidelines for the diagnosis and management of asthma. Update in selected topics 2002. J Allergy Clin Immunol 2002; 110 (Suppl.): S142-98.
3. Szefler SJ, Eigen H. Budesonide inhalation suspension: A nebulized corticosteroid for persistent asthma. J Allergy Clin Immunol 2002; 109: 730-42.
4. Pulmicort Respules. [package insert]. Wilmington, DE: AstraZeneca LP, 2005.
5. Lantner R, Rockoff JB, DeMasi J et al. Fatal varicella in a corticosteroid-dependent asthmatic receiving troleandomycin. Allergy Proc 1990; 11: 83-7.
6. Kasper WJ, Howe PM. Fatal varicella after a single course of corticosteroids. Pediatr Infect Dis J 1990; 9: 729-32.
7. Falliers CJ, Ellis EF. Corticosteroids and varicella: Six-year experience in an asthmatic population. Arch Dis Child 1965; 40: 593-99.
8. Dowell SF, Bresee JS. Severe varicella associated with steroid use. Pediatrics 1993; 92: 223-28.
9. Gatnash AA, Connolly CK. Fatal chickenpox pneumonia in an asthmatic patient on oral steroids and methotrexate. Thorax 1995; 50: 422-23.
10. Silk HJ, Guay-Woodford L, Perez-Atayde AR et al. Fatal varicella in steroid-dependent asthma. J Allergy Clin Immunol 1988; 81: 47-51.
11. Girsh LS, Yu M, Jones J et al. A study of the risk of mortality of varicella in patients with bronchial asthma or other allergic disease receiving corticosteroid therapy. Ann Allergy 1966; 24: 690-93.
12. Weinberg EG, Tuchinda M. Varicella in asthmatic children receiving alternate-day corticosteroid therapy. J Med Assoc Thailand 1973; 56: 140-43.
13. American Academy of Allergy Asthma and Immunology. Position statement: inhaled corticosteroids and severe viral infections. J Allergy Clin Immunol 1993; 92: 223-28.
14. National Asthma Education and Prevention Program. Expert Panel Report 2: Guidelines for the Diagnosis and Management of Asthma. Bethesda, MD: National Institutes of Health, National Heart, Lung, and Blood Institutes, NIH publication no. 97-4051, 1997.
15. American Academy of Allergy Asthma and Immunology. Position Statement: Inhaled Corticosteroids and Systemic Infections. Available at: http://www.aaai.org/media/resources/academy_statements/ position_statements/inhaled_systemic.asp. Accessed on 28 December 2004.
16. Welch MJ. Inhaled steroids and severe viral infections. J Asthma 1994; 31: 43-50.
17. Choong K, Zwaigenbaum L, Onyett H. Severe varicella after low dose inhaled corticosteroids. Pediatr Infect Dis J 1995; 14: 809-11.
18. Abzug MJ, Cotton MF. Severe chickenpox after intranasal use of corticosteroids. J Pediatr 1993; 123: 577-79.
19. American Academy of Pediatrics Committee on Infectious Diseases. Recommendations for the use of live attenuated varicella vaccine. Pediatrics 1995; 95: 791-96.
20. Verstraeten T, Jumaan AO, Mullooly JP et al. A retrospective cohort study of the association of varicella vaccine failure with asthma, steroid use, age at vaccination, and measles-mumps-rubella vaccination. Pediatrics 2003; 112: E98-103.
21. Baker JW, Mellon M, Wald J et al. A multiple-dosing, placebo controlled study of budesonide inhalation suspension given once or twice daily for treatment of persistent asthma in young children and infants. Pediatrics 1999; 103: 414-21.
22. Kemp JP, Skoner D, Szefler SJ et al. Once-daily budesonide inhalation suspension for the treatment of persistent asthma in infants and young children. Ann Allergy Asthma Immunol 1999; 83: 231-39.
23. Shapiro G, Mendelson L, Kraemer MJ et al. Efficacy and safety of budesonide inhalation suspension (Pulmicort Respules) in young children with inhaled steroid-dependent, persistent asthma. J Allergy Clin Immunol 1998; 102: 789-96.
24. Varivax. [package insert]. Whitehouse Station, NJ: Merck & Co., Inc, 2001.
25. Atkinson WL, Pickering LK, Schwartz B et al. General recommendations on immunization. Recommendations of the Advisory Committee on Immunization Practices (ACIP) and the American Academy of Family Physicians (AAFP). MMWR Recomm ReH 2002; 51 (RR02): 1-36. Available at: http://www.cdc.gov/ mmwr/preview/mmwrhtml/rr5102a1.htm. Accessed on 28 January 2005.
26. Prevention of varicella: Recommendations of the Advisory Committee on Immunization Practices. MMWR Recomm Rep 1996; 45 (RR11): 1-25. Available at: http://www.cdc.gov/mmwr/preview/mmwrhtml/0042990.htm. Accessed on 27 February 2005.
27. Krah DL, Cho I, Schofield T, Ellis RW. Comparison of gpELISA and neutralizing antibody responses to Oka/Merck live varicella vaccine (Varivax®) in children and adults. Vaccine 1997; 15: 61-4.
28. Provost PJ, Krah DL, Kuter BJ et al. Antibody assays suitable for assessing immune responses to live varicella vaccine. Vaccine 1991; 9: 23-8.
29. Wasmuth EH, Miller WJ. Sensitive enzyme-linked immunosorbent assay for antibody to varicella-zoster virus using purified VZV glycoprotein antigen. J Med Virol 1990; 32: 189-93.
30. Keller PM, Lonergan K, Neff BJ et al. Purification of individual varicella -zoster virus (VZV) glycoproteins gpI, gpII, and gpIII and their use in ELISA for detection of VZV glycoprotein-specific antibodies. J Virol Methods 1986; 14: 177-88.
31. Li S, Chan IS, Matthews H et al. Inverse relationship between six week postvaccination varicella antibody response to vaccine and likelihood of long term breakthrough infection. Pediatr Infect Dis J 2002; 21: 337-42.
32. White CJ, Kuter BJ, Hildebrand CS et al. Varicella vaccine (VARIVAX) in healthy children and adolescents: Results from clinical trials, 1987 to 1989. Pediatrics 1991; 87: 604-10.
33. Weibel RE, Neff BJ, Kuter BJ et al. Live attenuated varicella virus vaccine: Efficacy trial in healthy children. N Engl J Med 1984; 310: 1409-15.
34. Kuter BJ, Weibel RE, Guess HA et al. Oka/Merck varicella vaccine in healthy children: Final report of a 2-year efficacy study and 7-year follow-up studies. Vaccine 1991; 9: 643-47.
35. Kuter B, Matthews H, Shinefield H et al, and the Study Group for VARIVAX. Ten year follow-up of healthy children who received one or two injections of varicella vaccine. Pediatr Infect Dis J 2004; 23: 132-37.
36. Shinefield H, Black S, Thear M et al. Safety and immunogenicity of a measles, mumps, rubella and varicella vaccine given with combined Haemophilus influenzae type b conjugate/hepatitis B vaccines and combined diphtheria-tetanus-acellular pertussis vaccines. Pediatr Infect Dis J 2006; 25: 287-92.
37. Bergen R, Black S, Shinefield H et al. Safety of cold-adapted live attenuated influenza vaccine in a large cohort of children and adolescents. Pediatr Infect Dis J 2004; 23: 138-44.
38. Piedra PA, Gaglani MJ, Riggs M et al. Live attenuated influenza vaccine, trivalent, is safe in healthy children 18months to 4years, 5 to 9years, and 10 to 18years of age in a community-based, nonrandomized, open-label trial. Pediatrics 2005; 116: E397-407.
39. Cates CJ, Jefferson TO, Bara AI, Rowe BH. Vaccines for preventing influenza in people with asthma (Cochrane Review). Cochrane Database Syst Rev 2003: CD000364.pub2.
40. Irani A-M, Cruz-Rivera M, Fitzpatrick S, Hoag J, Smith JA. Effects of budesonide inhalation suspension on hypothalamic-pituitary-adrenal axis function in infants and young children with persistent asthma. Ann Allergy Asthma Immunol 2002; 88: 306-12.
41. Masten B, McWilliams B, Lipscomb M et al. Immune response to hepatitis B vaccine in asthmatic children. Pediatr Pulmonol 2003; 36: 522-28.
42. Hanania NA, Sockrider M, Castro M et al, from the American Lung Association Asthma Clinical Research Centers. Immune response to influenza vaccination in children and adults with asthma: Effect of corticosteroid therapy. J Allergy Clin Immunol 2004; 113: 717-24.
43. Fairchok MP, Trementozzi DP, Carter PS et al. Effect of prednisone on response to influenza virus in asthmatic children. Arch Pediatr Adolesc Med 1998; 152: 1191-95.
44. Park CL, Frank AL, Sullivan M et al. Influenza vaccination of children during acute asthma exacerbation and concurrent prednisone therapy. Pediatrics 1996; 98: 196-200.